Gaurang Shah of Geojit Financial Services told CNBC-TV18, "On Sun Pharmaceutical we have a reduce recommendation and we believe that a lot of good news which is already there, is factored into the price. So possibly move out from Sun Pharmaceutical into a Natco Pharma which we have a recommendation on the long term and long term is one year plus, not six-eight months."
He further added, "On Aurobindo Pharma too we have a positive coverage, but here again you need to have at least one year plus."
gshah_ys_sun_auropharma_28dec.mp4
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!